1. 1955. A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin vs. Amphotericin B Deoxycholate in the Treatment of Invasive Candidiasis in Neonates and Infants ≤3 Months of Age. (26th November 2018) Authors: Kim, Jason; Nakwa, Firdose Lambey; Motta, Fábio De Araujo; Lozada, Perla Salcedo; Alabaz, Derya; Liu, Hong; Bloise, Keisha; Dorr, Mary Beth; Gaffney, Leah J Anderson; Kartsonis, Nicholas Journal: Open forum infectious diseases Issue: Volume 5(2018)Supplement 1 Page Start: S565 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A randomized, double-blind trial investigating the efficacy of caspofungin versus amphotericin B deoxycholate in the treatment of invasive candidiasis in neonates and infants younger than 3 months of age. (5th October 2019) Authors: Kim, Jason; Nakwa, Firdose Lambey; Araujo Motta, Fábio; Liu, Hong; Dorr, Mary Beth; Anderson, Leah J; Kartsonis, Nicholas Journal: Journal of antimicrobial chemotherapy Issue: Volume 75:Number 1(2020) Page Start: 215 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Assessment of Bezlotoxumab Immunogenicity. Issue 3 (14th August 2019) Authors: Montgomery, Diana L.; Matthews, Randolph P.; Yee, Ka Lai; Tobias, Lori M.; Dorr, Mary Beth; Wrishko, Rebecca E. Journal: Clinical pharmacology in drug development Issue: Volume 9:Issue 3(2020) Page Start: 330 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Bezlotoxumab (BEZ) for Prevention of Clostridium difficile Infection (CDI) Recurrence (rCDI): Distinguishing Relapse from Reinfection with Whole Genome Sequencing (WGS). (4th October 2017) Authors: Dorr, Mary Beth; Zeng, Zhen; Wilcox, Mark; Li, Junhua; Poxton, Ian; Zhao, Hailong; Li, Xiaoyun; Guris, Dalya; Shaw, Peter Journal: Open forum infectious diseases Issue: Volume 4(2017)Supplement 1 Page Start: S388 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Bezlotoxumab (BEZ) for Prevention of Clostridium Difficile Infection (CDI) Recurrence (rCDI): Outcomes in Patients with Substantial Renal Impairment (SRI). (4th October 2017) Authors: Golan, Yoav; DuPont, Herbert L; Aldomiro, Fernando; Jensen, Erin H; Hanson, Mary E; Dorr, Mary Beth Journal: Open forum infectious diseases Issue: Volume 4(2017)Supplement 1 Page Start: S387 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Bezlotoxumab for prevention of Clostridium difficile infection recurrence: Distinguishing relapse from reinfection with whole genome sequencing. (February 2020) Authors: Zeng, Zhen; Zhao, Hailong; Dorr, Mary Beth; Shen, Judong; Wilcox, Mark H.; Poxton, Ian R.; Guris, Dalya; Li, Junhua; Shaw, Peter M. Journal: Anaerobe Issue: Volume 61(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence. (10th March 2018) Authors: Gerding, Dale N; Kelly, Ciaran P; Rahav, Galia; Lee, Christine; Dubberke, Erik R; Kumar, Princy N; Yacyshyn, Bruce; Kao, Dina; Eves, Karen; Ellison, Misoo C; Hanson, Mary E; Guris, Dalya; Dorr, Mary Beth Journal: Clinical infectious diseases Issue: Volume 67:Number 5(2018) Page Start: 649 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: 12-Month Observational Data From the Randomized Phase III Trial, MODIFY II. (28th December 2019) Authors: Goldstein, Ellie J C; Citron, Diane M; Gerding, Dale N; Wilcox, Mark H; Gabryelski, Lori; Pedley, Alison; Zeng, Zhen; Dorr, Mary Beth Journal: Clinical infectious diseases Issue: Volume 71:Number 4(2020) Page Start: 1102 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Bezlotoxumab Is Associated With a Reduction in Cumulative Inpatient-Days: Analysis of the Hospitalization Data From the MODIFY I and II Clinical Trials. (15th November 2018) Authors: Basu, Anirban; Prabhu, Vimalanand S; Dorr, Mary Beth; Golan, Yoav; Dubberke, Erik R; Cornely, Oliver A; Heimann, Sebastian M; Pedley, Alison; Xu, Ruifeng; Hanson, Mary E; Marcella, Stephen Journal: Open forum infectious diseases Issue: Volume 5:Number 11(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Corrigendum to: Renal Impairment, C. difficile Recurrence, and the Differential Effect of Bezlotoxumab: A Post Hoc Analysis of Pooled Data From 2 Randomized Clinical Trials. (20th January 2021) Authors: Golan, Yoav; DuPont, Herbert L; Aldomiro, Fernando; Jensen, Erin H; Hanson, Mary E; Dorr, Mary Beth Journal: Open forum infectious diseases Issue: Volume 8:Number 1(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗